1. Home
  2. PHAT vs EVGO Comparison

PHAT vs EVGO Comparison

Compare PHAT & EVGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAT
  • EVGO
  • Stock Information
  • Founded
  • PHAT 2018
  • EVGO 2010
  • Country
  • PHAT United States
  • EVGO United States
  • Employees
  • PHAT N/A
  • EVGO N/A
  • Industry
  • PHAT Biotechnology: Pharmaceutical Preparations
  • EVGO Other Specialty Stores
  • Sector
  • PHAT Health Care
  • EVGO Consumer Discretionary
  • Exchange
  • PHAT Nasdaq
  • EVGO Nasdaq
  • Market Cap
  • PHAT 769.0M
  • EVGO 674.8M
  • IPO Year
  • PHAT 2019
  • EVGO N/A
  • Fundamental
  • Price
  • PHAT $11.70
  • EVGO $4.65
  • Analyst Decision
  • PHAT Strong Buy
  • EVGO Strong Buy
  • Analyst Count
  • PHAT 5
  • EVGO 10
  • Target Price
  • PHAT $16.40
  • EVGO $6.10
  • AVG Volume (30 Days)
  • PHAT 1.3M
  • EVGO 4.6M
  • Earning Date
  • PHAT 11-06-2025
  • EVGO 11-11-2025
  • Dividend Yield
  • PHAT N/A
  • EVGO N/A
  • EPS Growth
  • PHAT N/A
  • EVGO N/A
  • EPS
  • PHAT N/A
  • EVGO N/A
  • Revenue
  • PHAT $114,039,000.00
  • EVGO $308,365,000.00
  • Revenue This Year
  • PHAT $213.11
  • EVGO $45.33
  • Revenue Next Year
  • PHAT $91.84
  • EVGO $26.67
  • P/E Ratio
  • PHAT N/A
  • EVGO N/A
  • Revenue Growth
  • PHAT 1049.82
  • EVGO 49.06
  • 52 Week Low
  • PHAT $2.21
  • EVGO $2.20
  • 52 Week High
  • PHAT $19.50
  • EVGO $9.07
  • Technical
  • Relative Strength Index (RSI)
  • PHAT 50.37
  • EVGO 55.48
  • Support Level
  • PHAT $10.33
  • EVGO $4.85
  • Resistance Level
  • PHAT $12.97
  • EVGO $5.15
  • Average True Range (ATR)
  • PHAT 0.89
  • EVGO 0.27
  • MACD
  • PHAT -0.11
  • EVGO -0.02
  • Stochastic Oscillator
  • PHAT 45.41
  • EVGO 42.78

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

About EVGO EVgo Inc.

EVgo owns and operates a public direct current fast-charging network in the US. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the US. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments, and independent property owners to locate and deploy its EV charging infrastructure.

Share on Social Networks: